TLR-MD2-fusion protein for the treatment of infectious diseases, chronic inflammatory diseases and sepsis
The recombinant TLR-MD-2 fusion protein or a fusion protein homopolymer / heteropolymer complex can be used for the prophylactic and/or therapeutic treatment of allergic reactions, infections diseases and inflammatory conditions, such as sepsis.
Further Information: PDF
Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Phone: +49 (0)89/1205-6000
Contact
Dr. Wolfgang Knappe
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Targeted use of enfortumab vedotin for the treatment of advanced urothelial carcinoma
New study identifies NECTIN4 amplification as a promising biomarker – Under the leadership of PD Dr. Niklas Klümper, Assistant Physician at the Department of Urology at the University Hospital Bonn…
A novel universal light-based technique
…to control valley polarization in bulk materials. An international team of researchers reports in Nature a new method that achieves valley polarization in centrosymmetric bulk materials in a non-material-specific way…
How evolution has optimised the magnetic sensor in birds
The magnetic sense of migratory birds is probably based on the protein cryptochrome 4, and a genetic study has now provided further support for this theory. A team of researchers…